Sprouty-Related EVH1 Domain Containing 1, Recombinant Protein

SPRED1 Human; Sprouty-Related EVH1 Domain Containing 1 Human Recombinant; Sprouty-Related EVH1 Domain Containing 1; SPRED1; Spred-1; hSpred1; NFLS

For Research Use Only. Not for use in diagnostic procedures.

E Coli

Greater than 80.0% as determined by SDS-PAGE.

The SPRED1 solution (0.5mg/1ml) contains 20mM Tris-HCl (pH 8.0) and 10% glycerol.
Sterile Filtered clear solution.

Small volumes of SPRED1 recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Introduction: Sprouty-Related EVH1 Domain Containing 1, also known as SPRED1, is a part of the Sprouty family of proteins and is phosphorylated by tyrosine kinase. SPRED1 inhibits growth-factor-mediated activation of MAP kinase. SPRED1 plays a role as a homodimer or as a heterodimer with SPRED2 to regulate activation of the MAP kinase cascade. SPRED1 is a negative regulator of hematopoiesis of bone marrow.

Description: SPRED1 Human Recombinant produced in E Coli is a single polypeptide chain containing 467 amino acids (1-444) and having a molecular mass of 52.9kDa.SPRED1 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

RECOMBINANT & NATURAL PROTEINS

50,477 Da

sprouty related, EVH1 domain containing 1

sprouty-related, EVH1 domain-containing protein 1

Sprouty-related, EVH1 domain-containing protein 1

Spred-1; hSpred1  [Similar Products]

SPRE1_HUMAN

SPRED1: Tyrosine kinase substrate that inhibits growth-factor- mediated activation of MAP kinase. Negatively regulates hematopoiesis of bone marrow. Defects in SPRED1 are the cause of neurofibromatosis type 1-like syndrome (NFLS). It is a disorder characterized mainly by cafe au lait macules without neurofibromas or other tumor manifestations of neurofibromatosis type 1, axillary freckling, and macrocephaly. Additional clinical manifestations include Noonan-like facial dysmorphism, lipomas, learning disabilities and attention deficit-hyperactivity.

Protein type: Inhibitor

Chromosomal Location of Human Ortholog: 15q14

Cellular Component: cytoplasm; cytosol; nucleoplasm; plasma membrane

Molecular Function: phosphatase binding; protein binding; protein kinase binding; protein serine/threonine kinase inhibitor activity; stem cell factor receptor binding

Biological Process: fibroblast growth factor receptor signaling pathway; inactivation of MAPK activity; MAPKKK cascade; positive regulation of DNA damage response, signal transduction by p53 class mediator

Disease: Legius Syndrome

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.